In clinical trials, Tirzepatide has been administered for up to 52 weeks, with studies extending up to 72 weeks
The drug enhances insulin secretion from pancreatic beta cells in a glucose-dependent manner, meaning it stimulates insulin release only when blood glucose levels are elevated
Common side effects (5% or more of patients) Nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, indigestion, injection site reactions Serious side effects (rare) Pancreatitis stop Zepbound and seek emergency care for severe, persistent abdominal pain radiating to the back Gallbladder disease upper right abdominal pain, fever, jaundice Severe allergic reactions facial swelling, throat tightening, difficulty breathing Acute kidney injury usually from dehydration due to prolonged vomiting or diarrhea Hypoglycemia most likely when combined with insulin or sulfonylureas in diabetic patients Increased resting heart rate Boxed warning: Tirzepatide caused thyroid C-cell tumors in animal studies
Zepbound (tirzepatide) is an FDA-approved prescription medication for chronic weight management in adults with obesity or those who are overweight with weight-related health conditions
While tirzepatide itself does not cause immunosuppression, maintaining adequate nutrition and hydration is important for patients on immunosuppressive regimens, especially if experiencing gastrointestinal side effects
A new personalized formula, compounded tirzepatide with vitamin B12, is now available for those who experience side effects while taking tirzepatide
